Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luxdegalutamide (JSB462) in Japanese Patients With Metastatic Castration-Resistant Prostate Cancer
jRCT2031250438Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2025
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of luxdegalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Novartis. Primary endpoints: Incidence and severity of dose limiting toxicities (DLTs) during the first cycle of treatment, Incidence rate of adverse events (AEs) and serious adverse events (SAEs) and 6 more. Started Dec 2025; status: active, not recruiting.
02
Drugs
luxdegalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on jRCT2031250438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250438.